Zuberitamab for EBV infection after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This trial tests a drug called zuberitamab to treat EBV infections that can occur after a stem cell transplant. The goal is to see if it helps control the virus and prevent serious complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor (allogeneic).
- You have an active EBV infection, shown by a high level of the virus in your blood or by a biopsy of affected tissue.
- You are 18 years or older.
- You do not have HIV, active hepatitis B, or active hepatitis C.
- You are well enough to be up and about (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This study tests whether a medication called rituximab can help prevent a type of cancer (PTLD) that sometimes develops in transplant patients whose body is fighting a reactivated virus (EBV). You may qualify if you've had an organ transplant, have high levels of EBV in your blood, and haven't yet developed this cancer.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.